WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results.

To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website at www.spyre.com.

For Investors:

Eric McIntyre, Spyre Therapeutics

SVP of Finance and Investor Relations

Eric.mcintyre@spyre.com

For Media:

Josie Butler, 1AB

josie@1abmedia.com

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026